Concepedia
Author
Paul Farrington
Also Known As
Paul Farrington, Paul M. Farrington
61
Publications
557
Citations
6
H-Index
0
Concepts
All Affiliations
×
All Concepts
5
541
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada, +22
Nature Communications
2019
327
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Richard A. Ward, Mark J. Anderton, Paul A. Bethel, +35
Journal of Medicinal Chemistry
75
Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Jeremy Karlin, Jasmine Allen, Syed Farhan Ahmad, +33
Molecular Cancer Therapeutics
2018
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Kyoko Nakamura, Ankur Karmokar, Paul Farrington, +9
Clinical Cancer Research
2021
52
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i> -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington, Emma Jane Davies, David M. Robinson, +27
2020
26
Page 1